Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Bizhen Zhu & Jianping Huang
- چاپ و سال / کشور: 2011
Description
Sirs, The long-term prognosis of idiopathic membranous nephropathy (IMN) in children and therapeutic options for IMN are controversial. The disease has been reported to be relatively insensitive to immunosuppressive therapy and approximately 5–21% of patients will progress to end-stage renal diseases [1]. Remuzzi et al. [2] prospectively treated eight adult patients with IMN with four weekly rituximab (RTX), 375 mg/m2. Proteinuria significantly decreased and six patients achieved complete remission. In the pilot study by Fervenza et al. [3], 15 adult patients with IMN received RTX (375 mg/m2, d1, and d15). At 12 months, this included two patients with proteinuria <0.3 g/day and six patients with proteinuria <3 g/day. In children, very limited experience is published. Therefore, we would like to report our experience in a 10-year-old boy with IMN who was successfully treated by rituximab.
Pediatr Nephrol (2011) 26:637–638 DOI 10.1007/s00467-010-1671-2 Received: 2 August 2010 / Revised: 23 September 2010 / Accepted: 27 September 2010 / Published online: 29 October 2010
